Article
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Advances in therapy - 1 Sept 2020
Lampertico Pietro, Mauss Stefan, Persico Marcello, Barclay Stephen T, Marx Steven, Lohmann Kristina, Bondin Mark, Zhang ZhenZhen, Marra Fiona, Belperio Pamela S, Wedemeyer Heiner, Flamm Steven
Abstract excerpt
INTRODUCTION: More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compensated cirrhosis in Europe and the USA, who would previously have received glecaprevir/pibrentasvir for 12 weeks. This label update was based on the EXPEDITION-8 study,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.